Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 33.23
(3.01%)
USD 33.23
(3.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 487.46 Million USD | -40.28% |
| 2022 | 816.3 Million USD | -6.53% |
| 2021 | 873.3 Million USD | 15.02% |
| 2020 | 759.24 Million USD | 34.41% |
| 2019 | 564.85 Million USD | 7.63% |
| 2018 | 524.78 Million USD | 234.29% |
| 2017 | 156.98 Million USD | 33.25% |
| 2016 | 117.81 Million USD | 68.65% |
| 2015 | 69.85 Million USD | 5.59% |
| 2014 | 66.15 Million USD | -14.67% |
| 2013 | 77.53 Million USD | 112.89% |
| 2012 | 36.41 Million USD | -17.77% |
| 2011 | 44.28 Million USD | -51.51% |
| 2010 | 91.32 Million USD | 6.13% |
| 2009 | 86.05 Million USD | 2.59% |
| 2008 | 83.88 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 358.37 Million USD | -4.41% |
| 2024 Q3 | 335.55 Million USD | -6.37% |
| 2024 Q1 | 374.92 Million USD | -23.09% |
| 2023 Q2 | 373.19 Million USD | -57.58% |
| 2023 Q1 | 879.65 Million USD | 7.76% |
| 2023 Q4 | 487.46 Million USD | 30.7% |
| 2023 FY | 487.46 Million USD | -40.28% |
| 2023 Q3 | 372.96 Million USD | -0.06% |
| 2022 Q4 | 816.3 Million USD | -2.86% |
| 2022 FY | 816.3 Million USD | -6.53% |
| 2022 Q1 | 811.07 Million USD | -7.13% |
| 2022 Q2 | 853.53 Million USD | 5.24% |
| 2022 Q3 | 840.33 Million USD | -1.55% |
| 2021 Q2 | 787.48 Million USD | 4.58% |
| 2021 Q4 | 873.3 Million USD | 17.29% |
| 2021 Q1 | 752.99 Million USD | -0.82% |
| 2021 FY | 873.3 Million USD | 15.02% |
| 2021 Q3 | 744.57 Million USD | -5.45% |
| 2020 Q3 | 801.14 Million USD | -2.9% |
| 2020 Q1 | 576.48 Million USD | 2.06% |
| 2020 Q2 | 825.04 Million USD | 43.12% |
| 2020 FY | 759.24 Million USD | 34.41% |
| 2020 Q4 | 759.24 Million USD | -5.23% |
| 2019 Q4 | 564.85 Million USD | 2.77% |
| 2019 FY | 564.85 Million USD | 7.63% |
| 2019 Q1 | 545.43 Million USD | 3.93% |
| 2019 Q2 | 540.77 Million USD | -0.85% |
| 2019 Q3 | 549.65 Million USD | 1.64% |
| 2018 Q1 | 473.29 Million USD | 201.49% |
| 2018 Q4 | 524.78 Million USD | 4.84% |
| 2018 FY | 524.78 Million USD | 234.29% |
| 2018 Q3 | 500.57 Million USD | 8.28% |
| 2018 Q2 | 462.3 Million USD | -2.32% |
| 2017 Q3 | 133.81 Million USD | 14.4% |
| 2017 FY | 156.98 Million USD | 33.25% |
| 2017 Q1 | 116.19 Million USD | -1.38% |
| 2017 Q2 | 116.97 Million USD | 0.67% |
| 2017 Q4 | 156.98 Million USD | 17.31% |
| 2016 FY | 117.81 Million USD | 68.65% |
| 2016 Q4 | 117.81 Million USD | 5.43% |
| 2016 Q3 | 111.74 Million USD | 43.98% |
| 2016 Q2 | 77.61 Million USD | 17.0% |
| 2016 Q1 | 66.33 Million USD | -5.04% |
| 2015 Q4 | 69.85 Million USD | 21.84% |
| 2015 FY | 69.85 Million USD | 5.59% |
| 2015 Q1 | 45.05 Million USD | -31.9% |
| 2015 Q2 | 51.8 Million USD | 14.98% |
| 2015 Q3 | 57.33 Million USD | 10.68% |
| 2014 Q1 | 68.5 Million USD | -11.64% |
| 2014 FY | 66.15 Million USD | -14.67% |
| 2014 Q4 | 66.15 Million USD | 9.88% |
| 2014 Q3 | 60.2 Million USD | -1.01% |
| 2014 Q2 | 60.82 Million USD | -11.22% |
| 2013 Q4 | 77.53 Million USD | -30.35% |
| 2013 FY | 77.53 Million USD | 112.89% |
| 2013 Q1 | 37.78 Million USD | 3.76% |
| 2013 Q2 | 96.08 Million USD | 154.26% |
| 2013 Q3 | 111.31 Million USD | 15.85% |
| 2012 Q1 | 42.92 Million USD | -3.07% |
| 2012 Q2 | 41.98 Million USD | -2.2% |
| 2012 FY | 36.41 Million USD | -17.77% |
| 2012 Q4 | 36.41 Million USD | -14.07% |
| 2012 Q3 | 42.38 Million USD | 0.95% |
| 2011 Q3 | 104.82 Million USD | 0.0% |
| 2011 Q4 | 44.28 Million USD | -57.75% |
| 2011 FY | 44.28 Million USD | -51.51% |
| 2010 FY | 91.32 Million USD | 6.13% |
| 2010 Q3 | 93.41 Million USD | 0.0% |
| 2010 Q4 | 91.32 Million USD | -2.24% |
| 2009 FY | 86.05 Million USD | 2.59% |
| 2009 Q4 | 86.05 Million USD | 0.0% |
| 2008 FY | 83.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 21.884% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -891.258% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1111.806% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -286.57% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -84.132% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -608.941% |
| Imunon, Inc. | 8.53 Million USD | -5614.38% |
| Dynavax Technologies Corporation | 375.02 Million USD | -29.981% |
| Editas Medicine, Inc. | 150.05 Million USD | -224.853% |
| FibroGen, Inc. | 585.72 Million USD | 16.777% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -149.037% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -906.215% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 52.182% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 79.733% |
| Verastem, Inc. | 71.18 Million USD | -584.781% |
| Zoetis Inc. | 9.29 Billion USD | 94.756% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 90.534% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -491.342% |
| Homology Medicines, Inc. | 118.53 Million USD | -311.245% |
| Nektar Therapeutics | 267.04 Million USD | -82.538% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -2328.683% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1207.146% |
| Perrigo Company plc | 6.04 Billion USD | 91.931% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 26.231% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.292% |
| Illumina, Inc. | 4.36 Billion USD | 88.835% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.06% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 97.63% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -90.059% |
| Waters Corporation | 3.47 Billion USD | 85.978% |
| Biogen Inc. | 12.04 Billion USD | 95.953% |
| Evolus, Inc. | 209.68 Million USD | -132.471% |
| Adicet Bio, Inc. | 37.12 Million USD | -1213.203% |
| bluebird bio, Inc. | 424.62 Million USD | -14.798% |
| Geron Corporation | 146.12 Million USD | -233.587% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 87.965% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 21.085% |
| Myriad Genetics, Inc. | 312.9 Million USD | -55.788% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -94.356% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 86.094% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1285.733% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 74.209% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 93.141% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 90.088% |
| OPKO Health, Inc. | 622.47 Million USD | 21.69% |
| Exelixis, Inc. | 678.44 Million USD | 28.15% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -324.573% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -3789.11% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -22.706% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 81.276% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 70.447% |
| Blueprint Medicines Corporation | 918.64 Million USD | 46.937% |
| Insmed Incorporated | 1.66 Billion USD | 70.666% |
| TG Therapeutics, Inc. | 169.08 Million USD | -188.293% |
| Incyte Corporation | 1.59 Billion USD | 69.386% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 58.885% |